Dimensional Fund Advisors LP increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 426.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 492,547 shares of the biopharmaceutical company’s stock after purchasing an additional 398,978 shares during the period. Dimensional Fund Advisors LP’s holdings in Celldex Therapeutics were worth $1,778,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of CLDX. Teachers Advisors LLC increased its position in shares of Celldex Therapeutics by 0.9% in the fourth quarter. Teachers Advisors LLC now owns 167,582 shares of the biopharmaceutical company’s stock worth $593,000 after purchasing an additional 1,433 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of Celldex Therapeutics by 106.7% in the first quarter. Canada Pension Plan Investment Board now owns 203,800 shares of the biopharmaceutical company’s stock worth $736,000 after purchasing an additional 105,200 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Celldex Therapeutics by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock worth $1,943,000 after purchasing an additional 5,616 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Celldex Therapeutics by 103.3% in the first quarter. UBS Asset Management Americas Inc. now owns 78,055 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 39,658 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in shares of Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock worth $238,000 after purchasing an additional 1,409 shares during the last quarter. Institutional investors own 56.69% of the company’s stock.

Celldex Therapeutics, Inc. (CLDX) traded up 2.44% during mid-day trading on Friday, hitting $2.52. The stock had a trading volume of 1,109,934 shares. The stock’s 50-day moving average price is $2.41 and its 200-day moving average price is $2.91. Celldex Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $5.02. The stock’s market cap is $323.42 million.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. During the same quarter in the previous year, the company posted ($0.32) EPS. The company’s revenue was up 175.5% compared to the same quarter last year. On average, analysts predict that Celldex Therapeutics, Inc. will post ($1.04) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/03/celldex-therapeutics-inc-cldx-shares-bought-by-dimensional-fund-advisors-lp.html.

Several analysts have issued reports on CLDX shares. Jefferies Group LLC reaffirmed a “hold” rating and issued a $3.50 target price (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Zacks Investment Research raised Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 target price for the company in a research note on Wednesday, May 31st. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Cowen and Company reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. Finally, Aegis reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $7.32.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related stocks with our FREE daily email newsletter.